| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cinnamon is a spice from inner bark from several tree species. Cinnamon refers primarily to bark extracts from Cinnamomum verum (Ceylon cinnamon) and Cinnamomum cassia. Bioactive constituents include cinnamaldehyde, cinnamic acid derivatives, procyanidins, and polyphenols. In cancer models, cinnamon extracts and cinnamaldehyde are most frequently reported to exert anti-proliferative, pro-apoptotic, anti-inflammatory, and anti-angiogenic effects. Mechanistic themes include suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, induction of mitochondrial apoptosis, and context-dependent ROS elevation in tumor cells. Some studies report inhibition of HIF-1α and glycolytic signaling, though cinnamon is not a direct enzymatic Warburg inhibitor. Effects vary substantially depending on species (Ceylon vs Cassia), preparation (aqueous vs ethanol extract), and dose. Human oncology data remain limited and largely preclinical. -Cinnamaldehyde (CA), an active compound derived from the natural plant cinnamon. CA is an aromatic aldehyde compound, constituting approximately 65% of cinnamon extract - See also HCA, a derivative of CA Biological activity, cinnamaldehyde from Ceylon cinnamon: Antimicrobial activity: 10-50 μM Antioxidant activity: 10-100 μM Anti-inflammatory activity: 20-50 μM Anticancer activity: 50-100 μM Cardiovascular health: 20-50 μM 5 g of Ceylon cinnamon might contain roughly between 30 mg and 150 mg of cinnamaldehyde, with an approximate mid-range estimate of about 70 mg. Assuming a moderate supplemental intake 50–200 mg of cinnamaldehyde, peak plasma levels might be anticipated in the vicinity of 1–10 μM. Primary mechanisms (ranked):
Bioavailability / PK relevance: Cinnamon is compositionally variable; cinnamaldehyde is lipophilic, rapidly absorbed and metabolized, and systemic exposure after oral intake is likely much lower than many in-vitro anticancer concentrations. Extract formulation, species, dose, food matrix, and first-pass metabolism materially affect exposure. In-vitro vs systemic exposure relevance: Many anticancer studies use extract concentrations or cinnamaldehyde levels that may exceed achievable free systemic exposure after ordinary oral intake. Local gastrointestinal exposure may be more plausible than systemic tumor exposure. Clinical evidence status: Preclinical for oncology. Cinnamon has human RCT/meta-analysis literature mainly in metabolic/inflammatory endpoints, but no established clinical anticancer indication. Translational constraints include variable extract chemistry, cassia coumarin hepatotoxicity risk, CYP/herb-drug interaction potential, and uncertain tumor-achievable exposure. Cinnamon Cancer Mechanism Table
TSF: P = 0–30 min (redox and early signaling effects), R = 30 min–3 hr (acute pathway modulation), G = >3 hr (apoptosis, angiogenesis, phenotype changes). |
| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 6356- | Eug, | Cin, | Investigating the Molecular Mechanisms of the Anticancer Effects of Eugenol and Cinnamaldehyde Against Colorectal Cancer (CRC) Cells In Vitro |
| - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | Caco-2 | - | in-vitro, | Nor, | NCM460 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:62 Target#:96 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid